EYPT News and Press, EyePoint Pharmaceuticals Inc. From 09/05/23

2023-09-05 17:18:20 ET Gainers: AeroVironment ( AVAV ) +13% . Consolidated Water  ( CWCO ) +6% . GitLab  ( GTLB ) +6% . Backblaze ( BLZE ) +5% . Gogo ( GOGO ) +5% . Losers: CSG Systems International ( CSGS ) -...

2023-08-29 10:00:37 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...

2023-08-21 08:31:19 ET Summary EyePoint Pharmaceuticals is developing the EYP-1901 treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy. Q2 2023 earnings show a decrease in net revenue, but the company has a strong cash position to fund ope...

WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Jay S. Duker, M.D., President and Chief Executive...

2023-08-02 13:10:02 ET EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2023 Earnings Call Transcript August 02, 2023 08:30 AM ET Company Participants George Elston - Chief Financial Officer Dr. Jay Duker - President, and Chief Executive Officer Conference Call Partici...

2023-08-02 07:11:00 ET EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q2 GAAP EPS of -$0.61 misses by $1.18 . Revenue of $9.1M (-21.6% Y/Y) misses by $33.03M . Net product revenue for the second quarter was $5.3 million, compared to net product reve...

–Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 – –Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy remains on track wi...

2023-08-01 13:49:14 ET EyePoint Pharmaceuticals ( NASDAQ: EYPT ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is $0.36 (vs. -$0.52 last year) and the consensus Revenue Estimate is $42.13M (vs. $11.6M ...

Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs Patient demographics demonstrate the Phase 2 DAVIO 2 population has a better baseline BCVA and decreased CST compared to the Phase 1...